RemeGen Co Ltd
-
RemeGen’s Telitacicept Gets Conditional Approval in China
China NMPA has granted conditional approval for conditional approval for RemeGen’s Telitacicept (RC-18) with theraputic indiction of Systemic Lupus Erythematosus(SLE) on Mar 10, 2021.
